Literature DB >> 9148023

Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon.

H Toyoda1, T Kumada, S Nakano, I Takeda, K Sugiyama, T Osada, S Kiriyama, Y Sone, M Kinoshita, T Hadama.   

Abstract

BACKGROUND/AIMS: We evaluated the significance of the quasispecies nature of HCV as a predictor of the response to alpha interferon therapy in patients with chronic hepatitis C.
METHODS: Natural alpha interferon was administered in 62 patients for 24 weeks (daily for 2 weeks, then three times weekly for 22 weeks) and factors were analyzed that could affect the response. HCV subtype, HCV RNA concentrations and the number of HCV quasispecies were evaluated before treatment. HCV RNA concentrations were measured by branched DNA probe assay. The number of HCV quasispecies was measured by fluorescence single-strand conformation polymorphism analysis.
RESULTS: The HCV RNA concentration (p < 0.0001), HCV subtype (p = 0.0076), and the number of HCV quasispecies (p = 0.0024) were significantly associated with a complete response. Multivariate analyses showed that the number of HCV quasispecies was an independent predictor of the disappearance of HCV RNA during the administration of alpha interferon, but did not predict a relapse after its completion. Pretreatment concentration of HCV RNA was the only factor that was related to a long-term disappearance of HCV RNA.
CONCLUSIONS: The number of HCV quasispecies was significantly related to the response to alpha interferon early in its administration. The pretreatment concentration of HCV RNA was mainly related to a relapse following completion of treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9148023     DOI: 10.1016/s0168-8278(97)80002-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

1.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

3.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

4.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

5.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

6.  Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.

Authors:  J M Pawlotsky; G Germanidis; P O Frainais; M Bouvier; A Soulier; M Pellerin; D Dhumeaux
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.

Authors:  James Lara; Guoliang Xia; Mike Purdy; Yury Khudyakov
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

8.  Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy.

Authors:  Ahmed A Al-Qahtani; George Kessie; Damian Dela Cruz; Faleh Z Al-Faleh; Mohammed N Al-Ahdal
Journal:  Ann Saudi Med       Date:  2010 Mar-Apr       Impact factor: 1.526

Review 9.  Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.

Authors:  H Le Guillou-Guillemette; S Vallet; C Gaudy-Graffin; C Payan; A Pivert; A Goudeau; F Lunel-Fabiani
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

10.  Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Authors:  Thomas J Chambers; Xiaofeng Fan; Deborah A Droll; Edgardo Hembrador; Tiffany Slater; Michael W Nickells; Lynn B Dustin; Adrian M Dibisceglie
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.